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DIRECT COMPARISON OF 
APREMILAST AND BEST 
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USING A DISCRETE EVENT 
SIMULATION  
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OUTLINE 
 Psoriatic Arthritis Disease Brief 
 Mechanism of action 
 Differences between Psoriatic Arthritis and 
Rheumatoid Arthritis 
 Current treatment 
 Discrete Event Simulation 
 Definition 
 Model Overview 
 Model Results 
PSORIATIC ARTHRITIS  
DISEASE BRIEF 
PSA IS A CHRONIC INFLAMMATORY DISEASE OF THE JOINTS 
AND SKIN RESULTING FROM AN UNCONTROLLED IMMUNE 
RESPONSE1 
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Inflammation 
Over-production of TNF-α as well as other cytokines, alters bone 
homeostasis, resulting in the joint damage seen in PsA4 
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Pain and Swelling  of Joints,   
Enthesitis, Dactylitis3 
1. Schafer. Biochem Pharmacol. 2012;83:1583 
2. Serezani et al. Am J Respir Cell Mol Biol. 2008;39:127  
3. Gottlieb et al. J Am Acad Dermatol. 2008;58:851 
4. Mensah et al. Curr Rheumatol Rep. 2008;10(4):311  
PSA DIFFERS FROM RHEUMATOID ARTHRITIS (RA) BASED 
ON THE PRESENCE OF PSORIATIC-ASSOCIATED CONDITIONS 
AND THE DISTRIBUTION AND APPEARANCE OF THE 
AFFECTED JOINTS 
Clinical 
Feature 
PsA RA 
Psoriatic skin 
lesions present 
Common No 
Psoriasis-
associated nail 
symptoms  
Common No 
Distribution of 
affected joints 
Often asymmetrical 
Various joints affected 
Symmetrical 
Primarily involving hands and 
wrists 
Appearance of 
the affected joint 
More generalized swelling 
Produce a sausage-like 
appearance in fingers or toes 
Pronounced swelling over joints 
(RA nodules) 
Disease 
progression 
Variable Predictable 
Rheumatoid 
factor status 
Seronegative Seropositive 
3. Gottlieb A, et al. J Am Acad Dermatol. 2008 May;58(5):851-64. 
• In 75% of cases, psoriasis precedes the 
joint disease. 
• In 15% of cases, the onset of skin disease 
is at the same time as onset of joint 
involvement. 
• In 10% of cases, the joint disease precedes 
the psoriasis. 
  
KEY CONCEPTS 
PSA AND QOL 
5. Husted JA, et al. Arthritis Rheum. Apr 2001;45(2):151-158. 
6. Salaffi F, et al. Health Qual Life Outcomes. 2009;7:25. 
7. Bhosle MJ, et al. Health Qual Life Outcomes. 2006;4:35. 
 For people with psoriatic arthritis, quality of life is impacted by 
both the physical symptoms of the disease and the emotional 
burden of sometimes disfiguring skin symptoms.  
 Compared to rheumatoid arthritis and ankylosing spondylitis, 
people with psoriatic arthritis report more psychosocial problems. 
 This finding fits with data from a survey of people with psoriasis, 
which found that 75 percent of patients believe the skin condition 
had a moderate to large negative impact on their quality of life, 
with alteration in their activities and work. 
PSA HAS A SIGNIFICANT NEGATIVE IMPACT 
ON HEALTH-RELATED QUALITY OF LIFE 
(HRQOL) 
8 
• Decreased QoL as measured by the Medical Outcomes Short-Form 36 
Questionnaire (SF-36) scores in patients with PsA compared to the 
general population:1 
• 19% of patients with PsA claimed their disease resulted in “marked 
physical limitations”2 
• 8.2% of patients sought assistance for home activities from friends or 
family3 
 
8Husted JA, et al. J Rheumatol. 1997 Mar;24(3):511-7. 
9Torre Alonso JC, et al. Br J Rheumatol. 1991 Aug;30(4):245-50. 
10Kimball AB, et al. J Drugs Dermatol. 2007 Mar;6(3):299-306. 
• Both physical functioning and emotional well-being are decreased. 
• In patients with PsA and psoriasis: 
– Arthritis component - greater impact on physical functioning 
– Psoriasis component - greater impact on emotional well-being 
• Skin lesions associated with poor self-image and distress from pruritus and pain.  
 EPIDEMIOLOGY 
Prevalence 5% - 40% of people with  psoriasis  
Race Affects Caucasians more than other races 
Gender Men and women equally affected 
Age of onset 40–50 years of age, can occur earlier 
11. Gladman DD. Rheum Dis Clin North Am 1992;18:247–56 
TREATMENT OPTIONS 
Mild Disease 
 NSAIDs 
 
Moderate to Severe Disease 
 Corticosteroids 
 
 Traditional DMARDs 
 MTX 
 Sulfasalazine 
 Leflunomide 
 
 Biologic DMARDs 
National Guideline Recommendations in 
Patients with PsA 
PsA Disease 
Status 
Mild NSAIDs 
Moderate/
Severe* 
DMARDs 
  -Leflunomide 
  -Sulfasalazine 
TNF inhibitors 
   -Adalimumab 
   -Etanercept 
   -Infliximab  
*No evidence supporting DMARDs ahead of TNF inhibitors (effect size: TNF inhibitors > 
traditional DMARDs). However, TNF inhibitors are recommended for patients who fail to 
respond to at least one DMARD therapy unless poor prognosis present. 
12. Ritchlin CT, et al. Ann Rheum Dis. 2009 Sept;68(9): 1387-94.  
Grade A=Based on evidence from meta-analysis of randomized controlled trials (RCT) or ≥ 1 RCT  
Adverse Effects Limit the Benefits of Therapy 
with Traditional Systemic DMARDs and 
Biologics  Traditional systemic agents 
• Methotrexate (MTX)  has weak and conflicting evidence in the 
management of  PsA with risks of serious toxic reactions.  
• MTX is not approved by the FDA 
• Leflunomide does not have FDA approval and requires monitoring 
for hepatic toxicity 
• Sulfasalazine  has limited evidence in the management of  PsA 
with rarely occurring serious toxicities. 
 Biologics 
• Mild injection-site/infusion reactions 
• Black box warning of risk of serious infections and malignancies 
- Increased risk of infection 
• Overall infections, odds ratio 1.18 (95% confidence 
interval, 1.05-1.33)2  
- Patients with PsA are at greater risk for mortality from 
infection. 
13. Enbrel Prescribing Information, http://pi.amgen.com/united_states/enbrel/derm/enbrel_pi.pdf 
The Significant Burden Associated with PsA 
 Patients with PsA: 
• Suffer from limited mobility, pain, inflammation and stiffness 
as well as skin lesions from psoriasis 
• Have a poorer quality of life 
• Are less likely to be employed and less likely to be productive 
• Incur higher healthcare costs 
 
 New PsA therapies are needed that demonstrate: 
• Effective Treatment in Patients with Active Psoriatic 
Arthritis 
• Improved Safety and Better Tolerability than Traditional 
DMARDS and Biologics 
• Patient Convenience over Injectable Biologics 
• Cost savings compared to Biologics 
APREMILAST 
Apremilast is a first-in-class PDE4 
inhibitor  
 MOA:  modulates pro-inflammatory and anti-
inflammatory mediators 
 Administration: oral and does not need dose 
adjustments 
 
This drug represents a novel treatment 
option for patients and can represent a 
delay in biologic therapy14  
14. Tencer T, et al. (2014) Economic evaluation of sequencing strategies in the treatment of psoriatic arthritis in the 
United States (abstract). Value in Health (17)3: A46. 
 
OUTCOME MEASURES OF PSA 
 ACR response criteria: 20%, 50%, 70%  
(validated in RA, not PsA) 
 Tender and swollen joint count  
(modified for PsA to include DIP and CMC joints: 78/76, 
68/66) 
 3/5: patient global, physician global, patient pain, HAQ, 
acute phase reactant (sed rate, CRP) 
 Psoriatic Arthritis Response Criteria (PsARC) 
 Improvement in at least 2 of 4 criteria, including: 
 Physician global assessment (0–5) 
 Patient global assessment (0–5) 
 Tender joint score ( 30%) 
 Swollen joint score ( 30%) 
 Improvement in at least 1 of 2 joint scores 
 No worsening in any criteria 
DISCRETE EVENT SIMULATION 
All Models Are Wrong, But 
Some Are Useful 
 
-George E.P. Box 
DISCRETE EVENT SIMULATION (DES) 
 DES is a modeling technique that is event-based 
 
Advantages vs Markov Models 
 DES can incorporate new data as it becomes 
available 
 
 Can use an individual patient’s values and 
examine the decision from his or her point of view 
 
 Can capture multiple events with competing 
risks 
 
BASIC MODEL STRUCTURE 
 Patients with active psoriatic arthritis who have failed 
methotrexate (MTX) therapy will be split into two 
groups: apremilast followed by best supportive care 
(BSC) and patients only receiving BSC 
MTX 
Failure 
Apremilast  BSC 
BSC 
STEP 1: CREATE PATIENTS AND ASSIGN 
CHARACTERISTICS 
 Assign Baseline Utilities: 
 Age 
 Gender (45% male) 
 Life expectancy 
 Mortality 
STEP 2: PATIENTS ENTER EITHER APR OR 
BSC TREATMENT ARM 
 If ‘Is Patient starting a Trial?’ is TRUE, then 
patients enter APR arm 
 ‘Assign Time to Event TP’ sets the next event to 
death and logs the time at the beginning of the 
time-to-event period 
 Time advances in “Wait Next Event TP” 
STEP 2: PATIENTS ENTER EITHER APR OR 
BSC TREATMENT ARM 
 Patients move to ‘Assign QALYs and Costs TP’ 
where QALYs and Costs are calculated 
 The VBA module is used to calculate Other 
Healthcare Costs 
 The VBA module computes the patient’s age each 
month and tallies the costs over the course of the 
period 
STEP 2: PATIENTS ENTER EITHER APR OR 
BSC TREATMENT ARM 
 After costs and QALYs have been assigned, 
‘Death in TP?’ checks to see if the time of death 
event was prior to the end of the Trial Period 
 
 If so, patient is disposed of in the model, 
otherwise patient continues to BSC 
STEP 3: DECIDE IF TREATMENT WAS 
EFFECTIVE (OR NOT) 
 Patients enter a decision module (‘DECIDE 
outcome of Trial Period’) which decides whether 
the patients achieved a PsARC score (effective 
treatment) or not 
 If treatment effective, patients are assigned to a 
PASI group to allocate future costs and QALYs 
 Patients who are not successfully treated move to 
the BSC arm 
STEP 3: DECIDE IF TREATMENT WAS 
EFFECTIVE (OR NOT) 
 ‘Assign Time to Event PASI’ module assigns a 
length of time until patients move to BSC 
 Similar to the Trial Period arm, patient is 
advanced in time through the ‘Wait Next Event 
PASI’ module to the sooner of either Death or 
BSC or model end 
 Costs and QALYs are assigned as in Trial Period 
arm 
STEP 4: BSC, DEATH, OR MODEL END 
 Patients enter BSC arm either at beginning of 
the model run or through discontinuation of 
treatment 
 Similar to Trial Period and Apremilast Arm, with 
patients disposed of at the end 
 The Excel read/write modules are also shown 
MODEL ASSUMPTIONS 
 Patients who enter the BSC arm do not go back 
to apremilast therapy 
 There are no changes to BSC or treatment 
paradigms of PsA in clinical practice over the 
time horizon of the model (5 years) 
 The population to which the model is applied to 
follows the age and life expectancy of that in the 
model 
 HAQ scores return to baseline after 
discontinuation of treatment 
 No monitoring or lab costs for apremilast 
MODEL LIMITATIONS 
 Data was sourced from clinical trials and not real 
world 
 
 PASI is used as the trial period endpoint, but is 
not the clinical trial endpoint for efficacy 
 
 Indirect costs of treatment are not accounted for 
in the model 
 
MODEL RESULTS 
QALY/ 
patient 
Cost/ 
patient 
Markov 
Model 
0.29 $41,338 
DES 0.86 $33,888 
Comparison of DES to Markov 
Model 
 
• Model cost results are within 
20% 
CONCLUSIONS 
 DES models are more adaptable, compared to 
Markov models 
 Once data becomes available, for example QOL 
instrument data, the DES is easily updated 
 
 DES and Markov models share limitations, 
specifically the availability and quality of data 
 Markov models have less data requirements 
 
 A comparison of two models with the same data 
shows differences that can be attributed to  
 time to event that was used to calculate drop off to 
BSC 
 distributions used for age and life expectancy 
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